Codagenix, Inc., a Farmngdale, N.Y.-based clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, closed a $20m Series B funding round.

Its recoded vaccine candidates match to the target virus and induce an immune response to all viral antigens.

For cancer, the company’s nimble platform allows them to turn a virus into a potential oncolytic immuno-oncology therapies.

Codagenix spun out of the laboratory of National Academy of Science Member Eckard Wimmer at Stony Brook University in 2012.

This funding round, combined with Series A investments, brings Codagenix’s total funding to $38m. | To read full story, visit https://startuparound.com/read/1578951109.3707151/Codagenix-Raises-$20M-in-Series-B-Funding?ref=audio_experience